Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

The Outcome of Post-Chemotherapy Retroperitoneal Lymph Node Dissection in Patients with Metastatic Bladder Cancer in the Retroperitoneum.

Liu NW, Murray KS, Donat SM, Herr HW, Bochner BH, Dalbagni G.

Bladder Cancer. 2019 Jan 31;5(1):13-19. doi: 10.3233/BLC-180186.

2.

Propensity-matched analysis of patient-reported outcomes for neoadjuvant chemotherapy prior to radical cystectomy.

Feuerstein MA, Goldstein L, Reaves B, Sun A, Goltzman M, Morganstern BA, Shabsigh A, Bajorin DF, Rosenberg JE, Donat SM, Herr HW, Laudone VP, Atkinson TM, Li Y, Dalbagni G, Rapkin B, Bochner BH.

World J Urol. 2019 Feb 23. doi: 10.1007/s00345-019-02692-z. [Epub ahead of print]

PMID:
30798382
3.

Comparison of Postradical Cystectomy Ileus Rates Using GIA-80 Versus GIA-60 Intestinal Stapler Device.

Ghanaat M, Winer AG, Sjoberg DD, Poon BY, Kashan M, Tin AL, Sfakianos JP, Cha EK, Donahue TF, Dalbagni G, Herr HW, Bochner BH, Vickers AJ, Donat SM.

Urology. 2018 Dec;122:121-126. doi: 10.1016/j.urology.2018.09.010. Epub 2018 Sep 20.

PMID:
30244117
4.

Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes.

Bochner BH, Dalbagni G, Marzouk KH, Sjoberg DD, Lee J, Donat SM, Coleman JA, Vickers A, Herr HW, Laudone VP.

Eur Urol. 2018 Oct;74(4):465-471. doi: 10.1016/j.eururo.2018.04.030. Epub 2018 May 18.

5.

Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.

Iyer G, Balar AV, Milowsky MI, Bochner BH, Dalbagni G, Donat SM, Herr HW, Huang WC, Taneja SS, Woods M, Ostrovnaya I, Al-Ahmadie H, Arcila ME, Riches JC, Meier A, Bourque C, Shady M, Won H, Rose TL, Kim WY, Kania BE, Boyd ME, Cipolla CK, Regazzi AM, Delbeau D, McCoy AS, Vargas HA, Berger MF, Solit DB, Rosenberg JE, Bajorin DF.

J Clin Oncol. 2018 Jul 1;36(19):1949-1956. doi: 10.1200/JCO.2017.75.0158. Epub 2018 May 9.

6.

Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma.

Isharwal S, Huang H, Nanjangud G, Audenet F, Chen YB, Gopalan A, Fine SW, Tickoo SK, Lee BH, Iyer G, Chadalavada K, Rosenberg JE, Bajorin DF, Herr HW, Donat SM, Dalbagni G, Bochner BH, Solit DB, Reuter VE, Al-Ahmadie HA.

Hum Pathol. 2018 Jul;77:63-69. doi: 10.1016/j.humpath.2018.03.015. Epub 2018 Mar 27.

7.

Clinical Outcomes of Patients With T1 Nested Variant of Urothelial Carcinoma Compared to Pure Urothelial Carcinoma of the Bladder.

Mally AD, Tin AL, Lee JK, Satasivam P, Cha EK, Donat SM, Herr HW, Bochner BH, Sjoberg DD, Dalbagni G.

Clin Genitourin Cancer. 2017 Jul 14. pii: S1558-7673(17)30199-4. doi: 10.1016/j.clgc.2017.07.002. [Epub ahead of print]

8.

Is restaging transurethral resection necessary in patients with non-muscle invasive bladder cancer and limited lamina propria invasion?

Audenet F, Retinger C, Chien C, Benfante NE, Bochner BH, Donat SM, Herr HW, Dalbagni G.

Urol Oncol. 2017 Oct;35(10):603.e1-603.e5. doi: 10.1016/j.urolonc.2017.06.042. Epub 2017 Jul 6.

9.

Commentary: Does Asymptomatic Bacteriuria Reduce the Risk of Recurrence of Non-muscle-invasive Bladder Tumors?

Herr H, Donat SM.

Urology. 2016 Dec;98:1-3. doi: 10.1016/j.urology.2016.07.033. Epub 2016 Aug 2. No abstract available.

PMID:
27496297
10.

Reply: To PMID 25623694.

Al Hussein Al Awamlh B, Lee RK, Chughtai B, Donat SM, Sandhu JS, Herr HW.

Urology. 2015 Feb;85(2):387. doi: 10.1016/j.urology.2014.09.043. No abstract available.

PMID:
25623696
11.

A cost-effectiveness analysis of management of low-risk non-muscle-invasive bladder cancer using office-based fulguration.

Al Hussein Al Awamlh B, Lee R, Chughtai B, Donat SM, Sandhu JS, Herr HW.

Urology. 2015 Feb;85(2):381-6. doi: 10.1016/j.urology.2014.09.041.

PMID:
25623694
12.

Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial.

Bochner BH, Dalbagni G, Sjoberg DD, Silberstein J, Keren Paz GE, Donat SM, Coleman JA, Mathew S, Vickers A, Schnorr GC, Feuerstein MA, Rapkin B, Parra RO, Herr HW, Laudone VP.

Eur Urol. 2015 Jun;67(6):1042-1050. doi: 10.1016/j.eururo.2014.11.043. Epub 2014 Dec 8.

13.

Adherence to surveillance guidelines after radical cystectomy: a population-based analysis.

Ehdaie B, Atoria CL, Lowrance WT, Herr HW, Bochner BH, Donat SM, Dalbagni G, Elkin EB.

Urol Oncol. 2014 Aug;32(6):779-84. doi: 10.1016/j.urolonc.2014.01.024. Epub 2014 Jun 13.

PMID:
24935876
14.

Gender disparities in hematuria evaluation and bladder cancer diagnosis: a population based analysis.

Garg T, Pinheiro LC, Atoria CL, Donat SM, Weissman JS, Herr HW, Elkin EB.

J Urol. 2014 Oct;192(4):1072-7. doi: 10.1016/j.juro.2014.04.101. Epub 2014 May 14.

15.

Clinical outcome of patients with T1 micropapillary urothelial carcinoma of the bladder.

Spaliviero M, Dalbagni G, Bochner BH, Poon BY, Huang H, Al-Ahmadie HA, Donahue TF, Taylor JM, Meeks JJ, Sjoberg DD, Donat SM, Reuter VE, Herr HW.

J Urol. 2014 Sep;192(3):702-7. doi: 10.1016/j.juro.2014.02.2565. Epub 2014 Mar 3.

16.

A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy.

Yamada Y, Kollmeier MA, Pei X, Kan CC, Cohen GN, Donat SM, Cox BW, Zelefsky MJ.

Brachytherapy. 2014 Mar-Apr;13(2):111-6. doi: 10.1016/j.brachy.2013.11.005. Epub 2013 Dec 25.

17.

Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience.

Bazzi WM, Kopp RP, Donahue TF, Bernstein M, Russo P, Bochner BH, Donat SM, Dalbagni G, Herr HW.

Int Sch Res Notices. 2014 Nov 13;2014:702653. doi: 10.1155/2014/702653. eCollection 2014.

18.

Preoperative serum albumin is associated with mortality and complications after radical cystectomy.

Garg T, Chen LY, Kim PH, Zhao PT, Herr HW, Donat SM.

BJU Int. 2014 Jun;113(6):918-23. doi: 10.1111/bju.12405.

19.

Upper tract imaging surveillance is not effective in diagnosing upper tract recurrence in patients followed for nonmuscle invasive bladder cancer.

Sternberg IA, Keren Paz GE, Chen LY, Herr HW, Donat SM, Bochner BH, Dalbagni G.

J Urol. 2013 Oct;190(4):1187-91. doi: 10.1016/j.juro.2013.05.020. Epub 2013 May 13.

PMID:
23680310
20.

Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.

Sternberg IA, Dalbagni G, Chen LY, Donat SM, Bochner BH, Herr HW.

J Urol. 2013 Nov;190(5):1686-91. doi: 10.1016/j.juro.2013.04.120. Epub 2013 May 7.

PMID:
23665400
21.

Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline.

Donat SM, Diaz M, Bishoff JT, Coleman JA, Dahm P, Derweesh IH, Herrell SD 3rd, Hilton S, Jonasch E, Lin DW, Reuter VE, Chang SS.

J Urol. 2013 Aug;190(2):407-16. doi: 10.1016/j.juro.2013.04.121. Epub 2013 May 7.

PMID:
23665399
22.

Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer.

Meeks JJ, Taylor JM, Matsushita K, Herr HW, Donat SM, Bochner BH, Dalbagni G.

BJU Int. 2013 Jun;111(8):E325-30. doi: 10.1111/j.1464-410X.2012.11751.x. Epub 2013 Feb 5.

23.

12th Annual meeting of the Society of Urologic Oncology (SUO) bladder cancer sessions I and II summary report.

Chang SS, Dinney CP, Donat SM, Dahm P, Gore JL, Lotan Y, Parekh DJ, Solit DB, O'Donnell PH, Feng FY, Hansel D, Milowsky MI.

Urol Oncol. 2012 Nov-Dec;30(6):944-7. doi: 10.1016/j.urolonc.2012.07.006.

PMID:
23218073
24.

Urinary diversion practice patterns among certifying American urologists.

Silberstein JL, Poon SA, Maschino AC, Lowrance WT, Garg T, Herr HW, Donat SM, Dalbagni G, Bochner BH, Sandhu JS.

J Urol. 2013 Mar;189(3):1042-7. doi: 10.1016/j.juro.2012.08.240. Epub 2012 Sep 23.

25.

Assessment of complication and functional outcome reporting in the minimally invasive prostatectomy literature from 2006 to the present.

Hakimi AA, Faleck DM, Sobey S, Ioffe E, Rabbani F, Donat SM, Ghavamian R.

BJU Int. 2012 Jan;109(1):26-30; discussion 30. doi: 10.1111/j.1464-410X.2011.10591.x. Epub 2011 Sep 27. Review.

26.

Evaluating the utility of a preoperative nomogram for predicting 90-day mortality following radical cystectomy for bladder cancer.

Taylor JM, Feifer A, Savage CJ, Maschino AC, Bernstein M, Herr HW, Donat SM.

BJU Int. 2012 Mar;109(6):855-9. doi: 10.1111/j.1464-410X.2011.10391.x. Epub 2011 Jul 1.

27.

Bacillus Calmette-Guérin without maintenance therapy for high-risk non-muscle-invasive bladder cancer.

Herr HW, Dalbagni G, Donat SM.

Eur Urol. 2011 Jul;60(1):32-6. doi: 10.1016/j.eururo.2011.03.051. Epub 2011 Apr 9.

PMID:
21497431
28.

A plea for a uniform surveillance schedule after radical cystectomy.

Dalbagni G, Bochner BH, Cronin A, Herr HW, Donat SM.

J Urol. 2011 Jun;185(6):2091-6. doi: 10.1016/j.juro.2011.01.082. Epub 2011 Apr 15.

PMID:
21496852
29.

Re: Khan et al.: analysis of early complications of robotic-assisted radical cystectomy using a standardized reporting system (Urology 2011;77:357-362).

Donat SM.

Urology. 2011 Apr;77(4):1016-7; author reply 1017. doi: 10.1016/j.urology.2010.04.064. No abstract available.

PMID:
21477742
30.
31.

Assessing urological complications of radiation therapy and surgical approaches for repair.

Donat SM.

J Urol. 2010 Dec;184(6):2233-4. doi: 10.1016/j.juro.2010.09.048. Epub 2010 Oct 16. No abstract available.

PMID:
20952006
32.

Reduced bladder tumour recurrence rate associated with narrow-band imaging surveillance cystoscopy.

Herr HW, Donat SM.

BJU Int. 2011 Feb;107(3):396-8. doi: 10.1111/j.1464-410X.2010.09547.x. Epub 2010 Aug 12.

33.

Clinical outcome of primary versus secondary bladder carcinoma in situ.

Chade DC, Shariat SF, Adamy A, Bochner BH, Donat SM, Herr HW, Dalbagni G.

J Urol. 2010 Aug;184(2):464-9. doi: 10.1016/j.juro.2010.03.134. Epub 2010 Jun 17.

34.

Clinical outcomes of primary bladder carcinoma in situ in a contemporary series.

Chade DC, Shariat SF, Godoy G, Savage CJ, Cronin AM, Bochner BH, Donat SM, Herr HW, Dalbagni G.

J Urol. 2010 Jul;184(1):74-80. doi: 10.1016/j.juro.2010.03.032.

35.

Editorial comment.

Donat SM.

Urology. 2010 May;75(5):1090; author reply 1090-1. doi: 10.1016/j.urology.2009.10.054. No abstract available.

PMID:
20451720
36.

Radical cystectomy in octogenarians--does morbidity outweigh the potential survival benefits?

Donat SM, Siegrist T, Cronin A, Savage C, Milowsky MI, Herr HW.

J Urol. 2010 Jun;183(6):2171-7. doi: 10.1016/j.juro.2010.02.015.

PMID:
20399461
37.

Variability of treatment selection among surgeons for patients with cT1 urothelial carcinoma.

Dalbagni G, Kaag M, Cronin A, Vora K, Bochner B, Donat SM, Herr HW.

BJU Int. 2010 Nov;106(10):1502-7. doi: 10.1111/j.1464-410X.2010.09347.x.

38.

Complications after radical and partial nephrectomy as a function of age.

Lowrance WT, Yee DS, Savage C, Cronin AM, O'Brien MF, Donat SM, Vickers A, Russo P.

J Urol. 2010 May;183(5):1725-30. doi: 10.1016/j.juro.2009.12.101. Epub 2010 Mar 17.

39.

Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer.

Yee DS, Shariat SF, Lowrance WT, Sterbis JR, Vora KC, Bochner BH, Donat SM, Herr HW, Dalbagni G, Sandhu JS.

J Urol. 2010 May;183(5):1751-6. doi: 10.1016/j.juro.2010.01.014. Epub 2010 Mar 17.

40.

Analysis of gender differences in early perioperative complications following radical cystectomy at a tertiary cancer center using a standardized reporting methodology.

Siegrist T, Savage C, Shabsigh A, Cronin A, Donat SM.

Urol Oncol. 2010 Jan-Feb;28(1):112-7. doi: 10.1016/j.urolonc.2009.04.012.

PMID:
20123360
41.

Editorial comment.

Donat SM.

J Urol. 2010 Mar;183(3):934. doi: 10.1016/j.juro.2009.11.120. Epub 2010 Jan 18. No abstract available.

PMID:
20083255
42.

Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer.

Dalbagni G, Vora K, Kaag M, Cronin A, Bochner B, Donat SM, Herr HW.

Eur Urol. 2009 Dec;56(6):903-10. doi: 10.1016/j.eururo.2009.07.005. Epub 2009 Jul 17.

PMID:
19632765
43.

Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies.

Lowrance WT, Thompson RH, Yee DS, Kaag M, Donat SM, Russo P.

BJU Int. 2010 Jan;105(1):16-20. doi: 10.1111/j.1464-410X.2009.08706.x. Epub 2009 Jul 6.

44.
45.

Quality control in transurethral resection of bladder tumours.

Herr HW, Donat SM.

BJU Int. 2008 Nov;102(9 Pt B):1242-6. doi: 10.1111/j.1464-410X.2008.07966.x. No abstract available.

PMID:
19035888
46.

Placement of transileal conduit retrograde nephroureteral stents in patients with ureteral obstruction after cystectomy: technique and outcome.

Alago W Jr, Sofocleous CT, Covey AM, Thornton RH, Donat SM, Brody LA, Getrajdman GI, Brown KT.

AJR Am J Roentgenol. 2008 Nov;191(5):1536-9. doi: 10.2214/AJR.08.1003.

PMID:
18941097
47.

A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.

Dash A, Pettus JA 4th, Herr HW, Bochner BH, Dalbagni G, Donat SM, Russo P, Boyle MG, Milowsky MI, Bajorin DF.

Cancer. 2008 Nov 1;113(9):2471-7. doi: 10.1002/cncr.23848.

48.

A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences.

Herr HW, Donat SM.

BJU Int. 2008 Nov;102(9):1111-4. doi: 10.1111/j.1464-410X.2008.07846.x. Epub 2008 Sep 3.

49.

Argument against frozen section analysis of distal ureters in transitional cell bladder cancer.

Donat SM.

Nat Clin Pract Urol. 2008 Oct;5(10):538-9. doi: 10.1038/ncpuro1210. Epub 2008 Sep 2. Review. No abstract available.

PMID:
18762781
50.

Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology.

Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, Raj G, Bochner BH, Dalbagni G, Herr HW, Donat SM.

Eur Urol. 2009 Jan;55(1):164-74. doi: 10.1016/j.eururo.2008.07.031. Epub 2008 Jul 18.

PMID:
18675501

Supplemental Content

Loading ...
Support Center